Literature DB >> 16493535

Onset of liver metastasis after histologically curative resection of pancreatic cancer.

Katsuhiko Inoue1, Takehisa Hiraoka, Keiichiro Kanemitsu, Hiroshi Takamori, Tatsuya Tsuji, Michio Kawasuji.   

Abstract

PURPOSE: We assessed the possibility of predicting the time of onset of liver metastases by measuring the postoperative changes in serum carbohydrate antigen (CA)19-9 after curative resection of pancreatic cancers.
METHODS: Among 28 patients who underwent histologically defined curative resection of pancreatic cancer between 1984 and 1999, liver metastasis developed in 11 patients with elevated serum CA19-9 levels. We plotted the serum CA19-9 levels against time on a semilogarithmic graph. Over the linear part of the curve, the time when log[CA19-9] equaled zero was defined as the time of onset of liver metastases. The log[CA19-9] level doubling time was then calculated and evaluated in relation to the survival period.
RESULTS: The serum CA19-9 levels increased linearly in 10 of the 11 patients. The predicted time of onset of liver metastasis ranged from preoperative day 163.0 to postoperative day 27.1, being preoperative in eight patients. The doubling time until death correlated strongly with survival in the eight patients with maintained log[CA19-9] linearity.
CONCLUSION: The onset of liver metastases might be preoperative in patients with advanced pancreatic cancer. Therefore, neoadjuvant chemotherapy should be mandatory even if there is no sign of liver metastases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493535     DOI: 10.1007/s00595-005-3143-z

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  15 in total

1.  Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal cancer.

Authors:  H J Staab; F A Anderer; E Stumpf; R Fischer
Journal:  Am J Surg       Date:  1978-09       Impact factor: 2.565

2.  Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.

Authors:  R A Abrams; L B Grochow; A Chakravarthy; T A Sohn; M L Zahurak; T L Haulk; S Ord; R H Hruban; K D Lillemoe; H A Pitt; J L Cameron; C J Yeo
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-15       Impact factor: 7.038

3.  Prognostic value of CA 19-9 serum course in pancreatic cancer.

Authors:  F Safi; W Schlosser; S Falkenreck; H G Beger
Journal:  Hepatogastroenterology       Date:  1998 Jan-Feb

4.  Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer.

Authors:  E Beretta; A Malesci; A Zerbi; A Mariani; M Carlucci; C Bonato; A M Ferrari; V Di Carlo
Journal:  Cancer       Date:  1987-11-15       Impact factor: 6.860

5.  Biliary CA 19-9 values correlate with the risk of hepatic metastases in patients with adenocarcinoma of the pancreas.

Authors:  R C Montgomery; J P Hoffma; E A Ross; L B Riley; J A Ridge; B L Eisenberg
Journal:  J Gastrointest Surg       Date:  1998 Jan-Feb       Impact factor: 3.452

6.  Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.

Authors:  R C Montgomery; J P Hoffman; L B Riley; A Rogatko; J A Ridge; B L Eisenberg
Journal:  Ann Surg Oncol       Date:  1997 Oct-Nov       Impact factor: 5.344

7.  The time of occurrence of liver metastasis in carcinoma of the pancreas.

Authors:  K Amikura; M Kobari; S Matsuno
Journal:  Int J Pancreatol       Date:  1995-04

8.  Combination of intraoperative radiation with resection of cancer of the pancreas.

Authors:  T Hiraoka; R Uchino; K Kanemitsu; M Toyonaga; N Saitoh; I Nakamura; S Tashiro; Y Miyauchi
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

9.  Disappearance curves for tumor markers after resection of intrathoracic malignancies.

Authors:  T Yoshimasu; S Maebeya; T Suzuma; T Bessho; H Tanino; J Arimoto; T Sakurai; Y Naito
Journal:  Int J Biol Markers       Date:  1999 Apr-Jun       Impact factor: 3.248

10.  Disappearance curves of tumor markers after radical surgery.

Authors:  M Rapellino; P Piantino; F Pecchio; E Ruffini; A Cavallo; E Scappaticci; S Baldi; E Ciocia; S Pivetti
Journal:  Int J Biol Markers       Date:  1994       Impact factor: 3.248

View more
  2 in total

1.  Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment.

Authors:  Masakazu Hashimoto; John David Konda; Stephanie Perrino; Maria Celia Fernandez; Andrew M Lowy; Pnina Brodt
Journal:  Mol Cancer Ther       Date:  2021-09-22       Impact factor: 6.009

2.  Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial.

Authors:  Ryuichiro Doi; Masayuki Imamura; Ryo Hosotani; Toshihide Imaizumi; Takashi Hatori; Ken Takasaki; Akihiro Funakoshi; Hideyuki Wakasugi; Takehide Asano; Shoichi Hishinuma; Yoshiro Ogata; Makoto Sunamura; Koji Yamaguchi; Masao Tanaka; Sonshin Takao; Takashi Aikou; Koichi Hirata; Hiroyuki Maguchi; Koichi Aiura; Tatsuya Aoki; Akira Kakita; Makoto Sasaki; Masahiko Ozaki; Satoru Matsusue; Shunichi Higashide; Hideki Noda; Seiyo Ikeda; Shunzo Maetani; Shigeaki Yoshida
Journal:  Surg Today       Date:  2008-10-29       Impact factor: 2.549

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.